MEDIPOST’s CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control

B – Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study – Japan Phase 3 results strengthen CARTISTEM’s®…
posteditor
posteditor
Articles: 17424

Other News